NASDAQ:EBIO Eleven Biotherapeutics (EBIO) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free EBIO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume15.58 million shsAverage Volume2.86 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Eleven Biotherapeutics alerts: Email Address Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Eleven Biotherapeutics Stock (NASDAQ:EBIO)Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Read More Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> EBIO Stock News HeadlinesDecember 2, 2023 | afr.com7-Eleven Australia’s family owners sell for $1.71bNovember 11, 2023 | mirror.co.ukEleven councillors quit Labour Party as Keir Starmer refuses to back Gaza ceasefireMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.August 16, 2023 | foxnews.comCalifornia mayor criticizes Prop 47 after 7-Eleven Sikh employees beat alleged thiefJuly 31, 2023 | usatoday.comFree Slurpees? Yes, here's how to get one today and Tuesday, 7-Eleven's 96th birthdayApril 9, 2023 | cbsnews.comChicago police close in on 7-Eleven robbery suspects in LawndaleJanuary 27, 2023 | dallasnews.comA downtown Dallas 7-Eleven that averaged one police call a day has closedJanuary 26, 2023 | nypost.comChef Daniel Humm’s all-vegan menu at Eleven Madison Park blossoms after rough patchMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.January 15, 2023 | abcnews.go.com7-Eleven adds new bright purple, zero-sugar Slurpee flavor to the mixJanuary 15, 2023 | foxnews.comEleven New Jersey police officers treated for fentanyl exposure during search, 5 suspects arrestedOctober 14, 2022 | finance.yahoo.com7-Eleven, Inc. Introduces Limited Time Only Green Apple Flavor to Slurpee LineupSeptember 27, 2022 | finance.yahoo.comAeglea BioTherapeutics, Inc. (AGLE)See More Headlines Receive EBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eleven Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2018Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EBIO CUSIPN/A CIK1485003 Webwww.elevenbio.com Phone(617) 444-8550FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesThomas R. CannellPresident, Chief Executive Officer & DirectorMonica ForbesChief Financial Officer & TreasurerJeannick CizeauHead of ResearchGlen C. MacDonaldChief Technology OfficerKirstin N. AndersonSenior Director-FinanceKey CompetitorsGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All Competitors EBIO Stock Analysis - Frequently Asked Questions How were Eleven Biotherapeutics' earnings last quarter? Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) issued its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. What other stocks do shareholders of Eleven Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eleven Biotherapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Immunomedics (IMMU), Dynavax Technologies (DVAX), Sesen Bio (SESN), iShares Preferred and Income Securities ETF (PFF) and Inovio Pharmaceuticals (INO). This page (NASDAQ:EBIO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eleven Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.